STAT3 and lung cancer: Additional studies identify oncrasin-72 as a novel STAT3 inhibitor that (i) suppresses proliferation across the NCI-60 cell line panel from diverse tissue origins, (ii) induces dose-dependent tumor regression in xenograft models, and (iii) significantly inhibits both tumor growth and STAT3 phosphorylation (p-STAT3) in lung cancer models.